Uchino U, Kanayama A, Hasegawa M, Kobayashi I, Muto H, Enogaki K, Matsunaga T, Ogawa M, Cyong J C, Kodama K
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories Inc.
Jpn J Antibiot. 1995 Sep;48(9):1119-30.
New macrolide antibiotic, azithromycin (AZM), was administered to six healthy male volunteers and its effects on their intestinal microflora were investigated. Each volunteer was given 500 mg of AZM orally, once a day for 3 consecutive days. Stool samples were obtained from them prior to the medication and 1, 7, 14 and 28 days after the third day the medication. A slight decrease in the total aerobic bacterial count was observed. Also, several species of anaerobic bacteria showed slight decreases through the 14th day post medication. Individual variances were observed, however. A marked decrease in the number of Bifidobacterium was found for each of the volunteers. Clostridium difficile was detected from one of the volunteers on the 28th day post medication without diarrhea related symptoms.
给六名健康男性志愿者服用了新型大环内酯类抗生素阿奇霉素（AZM），并研究了其对他们肠道微生物群的影响。每位志愿者口服500毫克AZM，连续3天，每天一次。在用药前以及用药第三天后的第1、7、14和28天从他们那里采集粪便样本。观察到需氧菌总数略有下降。此外，几种厌氧菌在用药后第14天之前也略有下降。然而，观察到个体差异。发现每位志愿者的双歧杆菌数量均显著减少。在用药后第28天从一名志愿者身上检测到艰难梭菌，但没有腹泻相关症状。
